Loading…
Vitamin-D receptor agonist calcitriol reduces calcification in vitro through selective upregulation of SLC20A2 but not SLC20A1 or XPR1
Vitamin D deficiency (hypovitaminosis D) causes osteomalacia and poor long bone mineralization. In apparent contrast, hypovitaminosis D has been reported in patients with primary brain calcifications (“Fahr’s disease”). We evaluated the expression of two phosphate transporters which we have found to...
Saved in:
Published in: | Scientific reports 2016-05, Vol.6 (1), p.25802-25802, Article 25802 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Vitamin D deficiency (hypovitaminosis D) causes osteomalacia and poor long bone mineralization. In apparent contrast, hypovitaminosis D has been reported in patients with primary brain calcifications (“Fahr’s disease”). We evaluated the expression of two phosphate transporters which we have found to be associated with primary brain calcification (
SLC20A2
, whose promoter has a predicted vitamin D receptor binding site and
XPR1
) and one unassociated (
SLC20A1
), in an
in vitro
model of calcification. Expression of all three genes was significantly decreased in calcifying human bone osteosarcoma (SaOs-2) cells. Further, we confirmed that vitamin D (calcitriol) reduced calcification as measured by Alizarin Red staining. Cells incubated with calcitriol under calcifying conditions specifically maintained expression of the phosphate transporter
SLC20A2
at higher levels relative to controls, by RT-qPCR. Neither
SLC20A1
nor
XPR1
were affected by calcitriol treatment and remained suppressed. Critically, knockdown of
SLC20A2
gene and protein with CRISPR technology in SaOs2 cells significantly ablated vitamin D mediated inhibition of calcification. This study elucidates the mechanistic importance of
SLC20A2
in suppressing the calcification process. It also suggests that vitamin D might be used to regulate
SLC20A2
gene expression, as well as reduce brain calcification which occurs in Fahr’s disease and normal aging. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep25802 |